Biogen Idec submits BLA for hemophilia A therapy

Biogen Idec Inc. (NASDAQ:BIIB) submitted a BLA to FDA for rFVIIIFc to treat hemophilia A. The long-acting recombinant fusion protein consisting of the Fc domain of human IgG1 attached to Factor VIII i...